Search

Eliana Y Polisecki

from Arlington, MA
Age ~50

Eliana Polisecki Phones & Addresses

  • 82 Lancaster Rd, Arlington, MA 02476 (781) 488-7427
  • Brighton, MA
  • Brookline, MA
  • West Newton, MA

Work

Company: Boston heart laboratory Position: Dr

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of Buenos Aires 1994 to 2004 Specialities: Molecular Biology, Biochemistry, Philosophy

Skills

Public Speaking • Teaching • Clinical Research • Data Analysis • Biotechnology • Pcr • Healthcare • Life Sciences • Team Leadership • Molecular Biology • Lifesciences • Bioinformatics • Mass Spectrometry • Research • Genetics • Science • Biochemistry • Statistics • Spanish

Industries

Hospital & Health Care

Resumes

Resumes

Eliana Polisecki Photo 1

Eliana Polisecki

View page
Location:
8700 Pershing Dr, Playa Del Rey, CA 90293
Industry:
Hospital & Health Care
Work:
Boston Heart Laboratory
Dr
Education:
University of Buenos Aires 1994 - 2004
Doctorates, Doctor of Philosophy, Molecular Biology, Biochemistry, Philosophy
Skills:
Public Speaking
Teaching
Clinical Research
Data Analysis
Biotechnology
Pcr
Healthcare
Life Sciences
Team Leadership
Molecular Biology
Lifesciences
Bioinformatics
Mass Spectrometry
Research
Genetics
Science
Biochemistry
Statistics
Spanish

Publications

Us Patents

Compositions And Methods For Treating And Preventing Coronary Heart Disease

View page
US Patent:
20130102582, Apr 25, 2013
Filed:
Oct 12, 2012
Appl. No.:
13/650948
Inventors:
Ernst J. Schaefer - Natick MA, US
Eliana Polisecki - Framingham MA, US
International Classification:
C12Q 1/68
US Classification:
51421002, 514510, 435 11, 435 611
Abstract:
The invention pertains to a method of determining a statin dosage for an individual in need of treatment with a statin, comprising determining a SLCO1B1 genotype from a nucleic acid sample of the individual, said genotype comprising the presence or absence of the SLCO1B1-056 polymorphism, and determining an ApoE genotype or phenotype identifying an ApoE polymorphism selected from the group consisting of ApoE2, ApoE3, ApoE4, and any combination thereof, wherein the combination of a SLCO1B1 genotype identifying the presence of the SLCO1B1-056 C polymorphism and the ApoE genotype or phenotype identifying one of the ApoE3/4 or ApoE4/4 genotypes indicates the statin dosage.

Compositions And Methods For Treating And Preventing Coronary Heart Disease

View page
US Patent:
20160040241, Feb 11, 2016
Filed:
Oct 23, 2015
Appl. No.:
14/921669
Inventors:
- Framingham MA, US
Eliana Polisecki - Framingham MA, US
International Classification:
C12Q 1/68
Abstract:
The invention pertains to a method of determining a statin dosage for an individual in need of treatment with a statin, comprising determining a SLCO1B1 genotype from a nucleic acid sample of the individual, said genotype comprising the presence or absence of the SLCO1B1-056 polymorphism, and determining an ApoE genotype or phenotype identifying an ApoE polymorphism selected from the group consisting of ApoE2, ApoE3, ApoE4, and any combination thereof, wherein the combination of a SLCO1B1 genotype identifying the presence of the SLCO1B1-056 C polymorphism and the ApoE genotype or phenotype identifying one of the ApoE3/4 or ApoE4/4 genotypes indicates the statin dosage.

Compositions And Methods For Treating And Preventing Coronary Heart Disease

View page
US Patent:
20140235607, Aug 21, 2014
Filed:
Apr 30, 2014
Appl. No.:
14/265862
Inventors:
- Framingham MA, US
Eliana Polisecki - Framingham MA, US
Assignee:
BOSTON HEART DIAGNOSTICS CORPORATION - Framingham MA
International Classification:
A61K 31/22
C12Q 1/68
A61K 31/397
US Classification:
51421002, 514510, 435 611, 506 9
Abstract:
The invention pertains to a method of determining a statin dosage for an individual in need of treatment with a statin, comprising determining a SLCO1B1 genotype from a nucleic acid sample of the individual, said genotype comprising the presence or absence of the SLCO1B1-056 polymorphism, and determining an ApoE genotype or phenotype identifying an ApoE polymorphism selected from the group consisting of ApoE2, ApoE3, ApoE4, and any combination thereof, wherein the combination of a SLCO1B1 genotype identifying the presence of the SLCO1B1-056 C polymorphism and the ApoE genotype or phenotype identifying one of the ApoE3/4 or ApoE4/4 genotypes indicates the statin dosage.
Eliana Y Polisecki from Arlington, MA, age ~50 Get Report